Penumbra

PEN

Market cap $13B

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ALAMEDA, Calif., April 13, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced 90-day results of the landmark STORM-PE randomized controlled trial (RCT), which found that patients with acute intermediate-high risk pulmonary embolism (PE) who were treated with computer assisted vacuum thrombectomy (CAVT™) plus anticoagulation achieved greater functional improvement, including walking significantly further and a higher proportion of patients achieving NYHA Class I (no physical limitations), compared to anticoagulation alone.

Penumbra (PEN) could produce exceptional returns because of its solid growth attributes.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Penumbra, Inc. (NYSE: PEN) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Penumbra will receive $374.00 in cash or 3.8721 shares of Boston Scientific common stock, subject to proration, for each share of Penumbra that they own. KSF is seeki.

Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?

PEN's expanding thrombectomy portfolio and global push fuel growth, but FX headwinds and macro risks may pressure near-term profitability.

Penumbra (PEN) could produce exceptional returns because of its solid growth attributes.

Wall Street loves growth stories. Venture capitalists love disruption stories.

Penumbra jumps after Q4 earnings and revenue beat, with double-digit sales growth, margin expansion and strong U.S. performance across key product lines.

While the top- and bottom-line numbers for Penumbra (PEN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.